Status:
COMPLETED
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
The Physicians' Services Incorporated Foundation
Conditions:
Transplant
Eligibility:
All Genders
18+ years
Brief Summary
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the li...
Eligibility Criteria
Inclusion
- Male or female patients who fulfill the following criteria are eligible for inclusion.
- CMV D+/R- liver, kidney and heart recipient
- CMV R+ liver,kidney and heart recipients who have received thymoglobulin induction therapy.
- D+/R- and R+ lung transplant recipients.
- Able to give written informed consent
- Are willing and able to comply with the protocol
- Age \>=18 years
Exclusion
- Patient unwilling or unable to give informed consent
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
End Date :
March 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00436384
Start Date
November 1 2005
End Date
March 1 2008
Last Update
April 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2N2